Extracellular vesicles metabolic changes reveals plasma signature in stage-dependent diabetic kidney disease

References

• Melmed S, Auchus RJ, Goldfine AB, et al. Williams textbook of endocrinology (Fourteenth Edition). 2020.
   Google Scholar
• Kidney Disease: Improving Global Outcomes Diabetes Work G. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4S):S1–S115.
   PubMedGoogle Scholar
• Justin G, Marie CB, Robert D, et al. Evidence of chronic kidney disease in veterans with incident diabetes mellitus. PLoS One. 2018;13(2):e0192712.
   PubMed Web of Science ®Google Scholar
• Pedrinelli R, Giampietro O, Carmassi F, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 1994;344(8914):14–18.
   PubMed Web of Science ®Google Scholar
• Kramer HJ, Nguyen QD, Curhan G, et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. J Am Med Assoc. 2003;289(24):3273–3277.
   PubMed Web of Science ®Google Scholar
• MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care. 2004;27(1):195–200.
   PubMed Web of Science ®Google Scholar
• Mottl AK, Kwon KS, Mauer M, et al. Normoalbuminuric diabetic kidney disease in the U.S. Population. J Diabetes Complications. 2013;27(2):123–127.
   PubMed Web of Science ®Google Scholar
• Tsalamandris C, Allen TJ, Gilbert RE, et al. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes. 1994;43(5):649–655.
   PubMed Web of Science ®Google Scholar
• Ekinci EI, Jerums G, Skene A, et al. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. Diabetes Care. 2013;36(11):3620–3626.
   PubMed Web of Science ®Google Scholar
• Gudehithlu KP, Garcia-Gomez I, Vernik J, et al. In diabetic kidney disease urinary exosomes better represent kidney specific protein alterations than whole urine. Am J Nephrol. 2015;42(6):418–424.
   PubMed Web of Science ®Google Scholar
• Sun AL, Deng JT, Guan GJ, et al. Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. Diab Vasc Dis Res. 2012;9(4):301–308.
   PubMed Web of Science ®Google Scholar
• Sakurai A, Ono H, Ochi A, et al. Involvement of Elf3 on Smad3 activation-dependent injuries in podocytes and excretion of urinary exosome in diabetic nephropathy. PLoS One. 2019;14(5):e0216788.
   PubMed Web of Science ®Google Scholar
• Delic D, Eisele C, Schmid R, et al. Urinary exosomal miRNA signature in type II diabetic nephropathy patients. PLoS One. 2016;11(3):e0150154.
   PubMed Web of Science ®Google Scholar
• Abe H, Sakurai A, Ono H, et al. Urinary exosomal mRNA of WT1 as diagnostic and prognostic biomarker for diabetic nephropathy. J Med Invest. 2018;65(3.4):208–215.
   PubMed Web of Science ®Google Scholar
• Cardenas-Gonzalez M, Srivastava A, Pavkovic M, et al. Identification, confirmation, and replication of novel urinary MicroRNA biomarkers in lupus nephritis and diabetic nephropathy. Clin Chem. 2017;63(9):1515–1526.
   PubMed Web of Science ®Google Scholar
• Barutta F, Bruno G, Matullo G, et al. MicroRNA-126 and micro-/macrovascular complications of type 1 diabetes in the EURODIAB prospective complications study. Acta Diabetol. 2017;54(2):133–139.
   PubMed Web of Science ®Google Scholar
• Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107(6):810–817.
   PubMed Web of Science ®Google Scholar
• He Y, Huang C, Lin X, et al. MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases. Biochimie. 2013;95(7):1355–1359.
   PubMed Web of Science ®Google Scholar
• Long J, Wang Y, Wang W, et al. MicroRNA-29c is a signature MicroRNA under high glucose conditions that targets sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem. 2011;286(13):11837–11848.
   PubMed Web of Science ®Google Scholar
• Wang B, Komers R, Carew R, et al. Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol. 2012;23(2):252–265.
   PubMed Web of Science ®Google Scholar
• Professional Practice Committee: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S3.
   PubMedGoogle Scholar
• Lou D, Wang Y, Yang Q, et al. Ultrafiltration combing with phospholipid affinity-based isolation for metabolomic profiling of urinary extracellular vesicles. J Chromatogr A. 2021;1640:461942.
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014;37(10):2864–2883.
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116(2):288–296.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Saigusa D, Kanemitsu Y, et al. Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nat Commun. 2019;10(1):1835.
   PubMedGoogle Scholar
• Linnan B, Yanzhe W, Ling Z, et al. In situ metabolomics of metabolic reprogramming involved in a mouse model of type 2 diabetic kidney disease. Front Physiol. 2021;12:779683.
   PubMed Web of Science ®Google Scholar
• Sirolli V, Rossi C, Di Castelnuovo A, et al. Toward personalized hemodialysis by low molecular weight amino-containing compounds: future perspective of patient metabolic fingerprint. Blood Transfus. 2012;10(Suppl 2):S78–S88.
   PubMedGoogle Scholar
• Ambati J, Chalam KV, Chawla DK, et al. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol. 1997;115(9):1161–1166.
   PubMed Web of Science ®Google Scholar
• Stoffel W, Sticht G, LeKim D. Metabolism of sphingosine bases. IX. Degradation in vitro of dihydrospingosine and dihydrospingosine phosphate to palmitaldehyde and ethanolamine phosphate. Hoppe Seylers Z Physiol Chem. 1968;349(12):1745–1748.
   PubMedGoogle Scholar
• Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9(2):139–150.
   PubMed Web of Science ®Google Scholar
• Burg N, Swendeman S, Worgall S, et al. Sphingosine 1-Phosphate receptor 1 signaling maintains endothelial cell barrier function and protects against immune complex-induced vascular injury. Arthritis Rheumatol. 2018;70(11):1879–1889.
   PubMed Web of Science ®Google Scholar
• Swendeman SL, Xiong Y, Cantalupo A, et al. An engineered S1P chaperone attenuates hypertension and ischemic injury. Sci Signal. 2017;10(492):eaal2722.
   PubMed Web of Science ®Google Scholar
• Daehn IS. Glomerular endothelial cell stress and Cross-Talk with podocytes in early [corrected] diabetic kidney disease. Front Med. 2018;5:76.
   Web of Science ®Google Scholar
• Sol M, Kamps JAAM, van den Born J, et al. Glomerular endothelial cells as instigators of glomerular sclerotic diseases. Front Pharmacol. 2020;11:573557.
   PubMed Web of Science ®Google Scholar
• Imasawa T, Kitamura H, Ohkawa R, et al. Unbalanced expression of sphingosine 1-phosphate receptors in diabetic nephropathy. Exp Toxicol Pathol. 2010;62(1):53–60.
   PubMedGoogle Scholar
• Yaghobian D, Don AS, Yaghobian S, et al. Increased sphingosine 1-phosphate mediates inflammation and fibrosis in tubular injury in diabetic nephropathy. Clin Exp Pharmacol Physiol. 2016;43(1):56–66.
   PubMed Web of Science ®Google Scholar
• Mitrofanova A, Drexler Y, Merscher S, et al. Role of sphingolipid signaling in glomerular diseases: focus on DKD and FSGS. J Cell Signal. 2020;1(3):56–69.
   PubMedGoogle Scholar
• Liu JJ, Ghosh S, Kovalik JP, et al. Profiling of plasma metabolites suggests altered mitochondrial fuel usage and remodeling of sphingolipid metabolism in individuals with type 2 diabetes and kidney disease. Kidney Int Rep. 2017;2(3):470–480.
   PubMed Web of Science ®Google Scholar
• Geoffroy K, Troncy L, Wiernsperger N, et al. Glomerular proliferation during early stages of diabetic nephropathy is associated with local increase of sphingosine-1-phosphate levels. FEBS Lett. 2005;579(5):1249–1254.
   PubMed Web of Science ®Google Scholar
• Boini KM, Zhang C, Xia M, et al. Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet. J Pharmacol Exp Ther. 2010;334(3):839–846.
   PubMed Web of Science ®Google Scholar
• Nicholson RJ, Pezzolesi MG, Summers SA. Rotten to the cortex: ceramide-mediated lipotoxicity in diabetic kidney disease. Front Endocrinol. 2020;11:622692.
   PubMed Web of Science ®Google Scholar
• Niewczas MA, Sirich TL, Mathew AV, et al. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int. 2014;85(5):1214–1224.
   PubMed Web of Science ®Google Scholar
• Eynard AR, Repossi G. Role of ω3 polyunsaturated fatty acids in diabetic retinopathy: a morphological and metabolically cross talk among blood retina barriers damage, autoimmunity and chronic inflammation. Lipids Health Dis. 2019;18(1):114.
   PubMedGoogle Scholar
• Mason RP, Libby P, Bhatt DL. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. 2020;40(5):1135–1147.
   PubMed Web of Science ®Google Scholar
• Lin L, Yu Q, Yan X, et al. Direct infusion mass spectrometry or liquid chromatography mass spectrometry for human metabonomics? A serum metabonomic study of kidney cancer. Analyst. 2010;135(11):2970–2978.
   PubMed Web of Science ®Google Scholar
• Dos Santos ALT, Duarte CK, Santos M, et al. Low linolenic and linoleic acid consumption are associated with chronic kidney disease in patients with type 2 diabetes. PLoS One. 2018;13(8):e0195249.
   PubMed Web of Science ®Google Scholar
• Dolezal M, Zitko J. Pyrazine derivatives: a patent review (June 2012 – present). Expert Opin Ther Pat. 2015;25(1):33–47.
   PubMed Web of Science ®Google Scholar
• Bownik A, Stępniewska Z. Ectoine as a promising protective agent in humans and animals. Arh Hig Rada Toksikol. 2016;67(4):260–265.
   PubMed Web of Science ®Google Scholar